Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
ESC 2018 – J&J not downhearted after Xarelto stumbles
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
